Tandem Diabetes Care

Tandem is repositioning t:slim X2 and Mobi from clinical 'power-user' tools to lifestyle-friendly automated delivery aimed squarely at the T2D mainstream — directly encroaching on simplicity-first competitors.

• Software-Updateable Hardware: Control-IQ+ ships OTA — turning the install base into a continuously-improving platform without hardware refresh cycles.
• Mobi Form Factor: Smallest tubed micro-pump on market closes the lifestyle gap to tubeless.
• Dual-CGM Strategy: Live Dexcom G6/G7 + Abbott Libre 3 Plus integration broadens patient addressable market.

• Insulet's pharmacy-channel cost advantage in T2D remains structural.
• Sequel + Tidepool Loop targets the same simplified-AID T2D segment with an open-source story.
• Senseonics integration narrative concentrates around competitors, leaving Tandem to defend a multi-CGM stance.

• Control-IQ+ T2D 510(k) clearance is the gating event for a 2025 commercial ramp.
• Mobi is the natural pump for the Type 2 patient who refuses a 'visible' device.
• Payer-led HbA1c outcomes contracts could turn algorithm advantage into reimbursement advantage.

• Continuously-updated algorithm via OTA — patients get better outcomes without hardware refresh.
• Mobi delivers tubed reliability at a tubeless-class footprint.
• Validated T2D pivotal data positions Tandem as a credible non-Insulet T2D choice.

• "Mobi is still tubed — why not go fully tubeless?"
  Mobi keeps the durable hardware advantage (longevity, refillable reservoir) while shrinking to a footprint patients actually wear. Total cost of ownership beats disposable pod stacks.
• "Is the OTA update story real or marketing?"
  Tandem has shipped >5 algorithm updates to the in-field install base since launch — no other AID vendor has matched the cadence.